Citizens reiterates CRISPR Therapeutics stock rating on label expansion potential

Citizens reiterates CRISPR Therapeutics stock rating on label expansion potential

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.